Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 2/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.38 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.37 |
| ▸ | EIF2S1 | P05198 | 1/20 | 0.37 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 7/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.36 |
| ▸ | FPR2 | P25090 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methane SCHEMBL985054 | 0.94 | DGAT1 (0.40) | TP53MAPK1EIF2S1EIF2AK3DGAT1 | |
| SCHEMBL28805613 | 0.94 | FYN (0.41) | TP53MAPK1FYNUSP7CHEK2 | |
| SCHEMBL4406324 | 0.92 | CA12 (0.44) | TP53MAPK1FYNUSP7CHEK2 | |
| SCHEMBL14398638 | 0.92 | FYN (0.38) | TP53FYNUSP7CHEK2EIF2S1 | |
| Methane SCHEMBL987128 | 0.91 | FYN (0.40) | FYNUSP7CHEK2EIF2S1EIF2AK3 | |
| SCHEMBL27918461 | 0.88 | EIF2S1 (0.36) | MAPK1FYNUSP7CHEK2EIF2S1 | |
| SCHEMBL27900677 | 0.88 | FYN (0.43) | FYNUSP7CHEK2EIF2S1EIF2AK3 | |
| SCHEMBL985051 | 0.86 | CA12 (0.41) | FYNEIF2S1EIF2AK3 | |
| SCHEMBL987126 | 0.86 | CHEK2 (0.41) | FYNUSP7CHEK2EIF2S1EIF2AK3 | |
| SCHEMBL986437 | 0.85 | FYN (0.44) | TP53FYNUSP7CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | claimed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | claimed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | TP53 424/4885MAPK1 521/4885FYN 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.